2024³â ´ëÇÑ°íÇ÷¾ÐÇÐȸ ´ë»çÁõÈıº¿¬±¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-07-20
±³À°ÀÏÀÚ : 2024-07-20
±³À°Àå¼Ò : ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø û¿øȦ(½Å°ü 1Ãþ)
±³À°ÁÖÁ¦ : (¿ÀÇÁ¶óÀÎ) 2024³â ´ëÇÑ°íÇ÷¾ÐÇÐȸ ´ë»çÁõÈıº¿¬±¸ ÇÏ°è ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ°íÇ÷¾ÐÇÐȸ
´ã´çÀÚ : ¼Áö¿ø
¿¬¶ôó : 02-565-3350
À̸ÞÀÏ : ksh5@koreanhypertension.org
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, °¡Á¤ÀÇÇаú, ÀÇ»çÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç
Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í "µî·Ïºñ Â÷µî ºÎ°úµÉ ¼ö ÀÖÀ½
´ëÇÑ°íÇ÷¾ÐÇÐȸ Á¤È¸¿ø : ¹«·á / ±× ¿Ü : »çÀüµî·Ï 2¸¸¿ø, ÇöÀåµî·Ï 3¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 08:30~08:50 Zilebesiran - RNA Interference Therapeutic Agent À̹ÎÈ£(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 08:50~09:10 Finerenone - Mineralocorticoid Receptor Antagonist Á¤Çѳª(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 09:10~09:30 Aprocitentan for Resistant HTN ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)
Åä·Ð 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 09:30~09:45 Åä·Ð ±è¼ºÀº, Á¶»óÈ£(ÇѸ²ÀÇ´ë, ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 10:00~10:20 Angiotensin Receptor-Neprilysin Inhibito ±èÇöÁø(ÇѾçÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 10:20~10:40 SGLT2 Inhibitor Á¤¹ÌÇâ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 10:40~11:00 GLP-1 Agonist À念¿ì(°¡ÃµÀÇ´ë)
Åä·Ð 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 11:00~11:15 Åä·Ð Á¶À±°æ, È«Á¤¾Ö(¿ï»êÀÇ´ë, ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 11:30~11:50 High-intensity Interval Training and HTN Á¦¼¼¿µ(¼¿ï½Ã¸³´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 11:50~12:10 Intermittent Fasting and HTN ±èº´½Ä(ÇѾçÀÇ´ë)
±³À°½Ã°£ 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 12:10~12:30 Low-carbohydrate/High-fat Diet and HTN ±è¿øÁø(Â÷ÀÇ´ë)
Åä·Ð 07¿ù 20ÀÏ Ã»¿øȦ(½Å°ü1Ãþ) 12:30~12:45 Åä·Ð ¼Àçºó, È«Áö¿¬(¼¿ïÀÇ´ë, ÇѸ²ÀÇ´ë)